Orthopedics

The PRP field in orthopedics has been plagued by inconsistency — some trials show clear benefit over hyaluronic acid and placebo, others show none. A 2025 systematic review by Berrigan et al. resolved this paradox: the variable was dose, not PRP itself. Studies delivering more than 5.5 billion platelets per injection reported positive outcomes in 90% of cases. Studies below 2.3 billion platelets consistently failed (P < 0.01).

This dose-response relationship has been independently validated. Patel et al. (2024) conducted a triple-blind RCT comparing 4 mL versus 8 mL PRP for early knee osteoarthritis. The higher-dose group showed significantly better WOMAC, VAS, and KOOS scores at 6 months (P < 0.001), with 96% patient satisfaction versus 68%.

But dose is only half the story. Standard PRP systems concentrate platelets by discarding platelet-poor plasma — and with it, therapeutic proteins that cannot be concentrated by centrifugation. Beitia et al. (2023) demonstrated that IGF-1 is the only growth factor correlated with cell proliferation in PRP, yet it shows zero enrichment in standard preparations because it resides in plasma, not platelets. Alpha-2-macroglobulin (A2M), the master protease inhibitor identified by Wang et al. (2014) as critical for cartilage protection, is similarly discarded.

autologIX addresses both axes. Its 48 mL blood draw is designed to deliver a higher total platelet dose, while ProtSmart 6 ultrafiltration enriches plasma proteins including IGF-1, HGF, A2M, and fibrinogen — creating a concentrated fibrin scaffold for sustained growth factor delivery. The ESSKA-ORBIT consensus (2024) now positions PRP as a valid first-line injectable treatment for mild-to-moderate knee osteoarthritis.

Clinical studies investigating autologIX outcomes are in development.